Understanding how certain immune cells affect multiple sclerosis
Contribution of the effector Treg-B-antibody nexus to the regulation of CNS autoimmunity
This study is looking at how certain immune cells called effector Tregs work in people with multiple sclerosis (MS) and how problems with these cells might make the disease worse, which could help find new ways to treat MS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10861734 on NIH RePORTER |
What this research studies
This research investigates the role of specific immune cells, known as effector Tregs, in the development and progression of multiple sclerosis (MS), a serious autoimmune disease affecting the central nervous system. By using a well-established animal model, the study aims to uncover how these cells maintain their regulatory functions during inflammation and how their dysfunction may contribute to the severity of MS. The researchers will explore the mechanisms behind the expression of a key transcription factor, Blimp1, in these immune cells and its impact on disease outcomes. This could lead to new insights into potential therapeutic targets for MS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis or those at risk of developing the condition.
Not a fit: Patients with other autoimmune diseases not related to multiple sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or even prevent the progression of multiple sclerosis.
How similar studies have performed: Previous research has shown promising results in understanding immune cell functions in autoimmune diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Leavenworth, Jianmei Wu — University of Alabama at Birmingham
- Study coordinator: Leavenworth, Jianmei Wu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.